Adverum Biotechnologies Appoints Angela Thedinga as Chief Technology Officer
February 25 2020 - 8:00AM
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene
therapy company targeting unmet medical needs in ocular and rare
diseases, today announced that Angela Thedinga has been promoted to
chief technology officer. Ms. Thedinga joined Adverum in August
2019 as the company’s vice president of program management and
strategy, and will now lead Adverum’s technology and operations
organization, including process development, manufacturing, and
supply chain management.
“I am pleased to congratulate Angela on her role as CTO, who
since joining the company has demonstrated executive leadership
across the organization and strategic insight,” said Leone
Patterson, president and chief executive officer of Adverum
Biotechnologies. “Angela’s deep experience transitioning and
expanding viral vector gene therapy manufacturing and analytical
capabilities from academic to commercial scale is increasingly
important to the growth of our business as we continue the
development and potential commercialization of ADVM-022, a novel
gene therapy to treat patients with serious ocular diseases.”
Before joining Adverum, Ms. Thedinga served as vice president of
program management and chief of staff at AveXis, Inc., a gene
therapy company acquired by Novartis in 2018. Ms. Thedinga was
instrumental in developing the early manufacturing strategy which
enabled AveXis to transition its early-stage AAV manufacturing
process to a scalable commercial manufacturing process. As chief of
staff at AveXis, Ms. Thedinga led the company-wide effort for the
global simultaneous regulatory submissions and the commercial
launch of Zolgensma®, the first systemically delivered AAV gene
therapy to receive approval by the U.S. Food and Drug
Administration. Earlier in her career, Ms. Thedinga held
manufacturing strategy roles of increasing responsibility at
Novartis AG and Abbott Laboratories.
Ms. Thedinga earned a Master’s degree in chemical engineering
from the Massachusetts Institute of Technology, a Master of
Business Administration from the MIT Sloan School of Management, a
Master of Public Health from the University of North Carolina at
Chapel Hill, and a Bachelor of Science in chemical engineering from
the University of Wisconsin. At MIT, Ms. Thedinga was a member of
the Leaders for Global Operations program and was named a Siebel
Scholar.
About Adverum BiotechnologiesAdverum
Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy
company targeting unmet medical needs in serious ocular and rare
diseases. Adverum is evaluating its novel gene therapy candidate,
ADVM-022, as a one-time, intravitreal injection for the treatment
of its lead indication, wet age-related macular degeneration. For
more information, please visit www.adverum.com.
Investor and Media Inquiries:Investors:Myesha
LacyAdverum Biotechnologies,
Inc.mlacy@adverum.com1-650-304-3892
Media:Cherilyn Cecchini, M.D.LifeSci
Communicationsccecchini@lifescicomms.com 1-646-876-5196
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Sep 2023 to Sep 2024